Evidence map›Paper›PMID 29449562›Full record

ArticleCell death & disease2018

Chir99021 and Valproic acid reduce the proliferative advantage of Apc mutant cells.

Alistair J Langlands, Thomas D Carroll, Yu Chen, Inke Näthke

Open access · goldAbstract read
In one paragraph

Article in Cell death & disease, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
0.9field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 24 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Differential sensitivity to Wnt signaling gradients in human gastric organoids derived from corpus and antrum.American journal of physiology. Gastrointestinal and liver physiology · 2023
    Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Alistair J LanglandsCell & Developmental Biology, School of Life Sciences, University of Dundee, Dundee, DD1 5EH, Scotland.
Thomas D CarrollCell & Developmental Biology, School of Life Sciences, University of Dundee, Dundee, DD1 5EH, Scotland.
Yu ChenCell & Developmental Biology, School of Life Sciences, University of Dundee, Dundee, DD1 5EH, Scotland.
Inke NäthkeCell & Developmental Biology, School of Life Sciences, University of Dundee, Dundee, DD1 5EH, Scotland. i.s.nathke@dundee.ac.uk.ORCID 0000-0003-2420-4385
University of Dundee · GB

Funding

Cancer Research UK 11243Medical Research CouncilNational Centre for the Replacement, Refinement and Reduction of Animals in Research NC/M001156/1Wellcome TrustWellcome Trust 097418/Z/11/ZWellcome Trust 097945/B/11/ZWellcome Trust 101468/Z/13/Z
6 · The paper itself

Abstract

More than 90% of colorectal cancers carry mutations in Apc that drive tumourigenesis. A 'just-right' signalling model proposes that Apc mutations stimulate optimal, but not excessive Wnt signalling, resulting in a growth advantage of Apc mutant over wild-type cells. Reversal of this growth advantage constitutes a potential therapeutic approach. We utilised intestinal organoids to compare the growth of Apc mutant and wild-type cells. Organoids derived from Apc

Indexed as

MutationAdenomatous Polyposis Coli ProteinAnimalsAntineoplastic AgentsApoptosisCell ProliferationGene Expression Regulation, NeoplasticHEK293 CellsHumansHydroxamic AcidsIntestinal PolyposisIntestine, SmallLoss of HeterozygosityMice, TransgenicPyridinesPyrimidinesAdenomatous Polyposis Coli Proteinadenomatous polyposis coli protein, mouseAntineoplastic AgentsChir 99021Hydroxamic AcidsPyridinesPyrimidinestrichostatin AValproic Acid

Identifiers

PMID29449562
PMCPMC5833359
OpenAlexW2794415594

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.